Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Lantern Pharma reported positive Phase 2 HARMONIC™ data for LP-300 in EGFR Exon 21 L858R-mutant NSCLC, showing that progression-free survival benefit deepens with treatment duration. Patients treated through up to six cycles achieved an 8.9-month median PFS, compared to 8.4 months in the overall L858R cohort, with a 77% clinical benefit rate and durable responses beyond two years.
Key figures
- Drug Name
- LP-300
- Phase Of Trial
- Phase 2
- Cohort size l858r
- 15
- Cohort size total
- 31
- Hazard ratio l858r
- 0.37
- Max cycles approved
- 8
- Median pfs l858r overall
- 8.4 months
- Median pfs l858r 6 cycles
- 8.9 months
- Tumor reduction rate l858r
- >70%
- Clinical benefit rate l858r
- 77%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.